Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study in Greece

Pulmonary Pharmacology and Therapeutics

Volumn 49, Issue , 2018, Pages 61-66

  Tzouvelekis, Argyrios ^a,b   Karampitsakos, Theodoros ^c   Kontou, Maria ^a   Granitsas, Andreas ^a   Malliou, Ioanna ^a   Anagnostopoulos, Aris ^a   Ntolios, Paschalis ^d   Tzilas, Vasilios ^a   Bouros, Evangelos ^a   Steiropoulos, Paschalis ^d   Chrysikos, Serafeim ^c   Dimakou, Katerina ^c   Koulouris, Nikolaos ^a   Bouros, Demosthenes ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

^c Hospital for Diseases of the Chest SOTIRIA   (Greece)

^d DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

NINTEDANIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE;

ABDOMINAL PAIN; ADJUVANT THERAPY; AGED; ARTICLE; BODY WEIGHT LOSS; DECREASED APPETITE; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EPISTAXIS; FATIGUE; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED VITAL CAPACITY; GREECE; HEADACHE; HEART INFARCTION; HUMAN; LIVER TOXICITY; LUNG DIFFUSION CAPACITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VOMITING; CLINICAL TRIAL; MORTALITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; VERY ELDERLY; VITAL CAPACITY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GREECE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 85042673761     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2018.01.006     Document Type: Article

References (45)

1. Raghu, G., Collard, H.R., Egan, J.J., Martinez, F.J., Behr, J., Brown, K.K., Colby, T.V., Cordier, J.F., Flaherty, K.R., Lasky, J.A., Lynch, D.A., Ryu, J.H., Swigris, J.J., Wells, A.U., Ancochea, J., Bouros, D., Carvalho, C., Costabel, U., Ebina, M., Hansell, D.M., Johkoh, T., Kim, D.S., King, T.E. Jr., Kondoh, Y., Myers, J., Muller, N.L., Nicholson, A.G., Richeldi, L., Selman, M., Dudden, R.F., Griss, B.S., Protzko, S.L., Schunemann, H.J., AEJACoIP, Fibrosis, An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183 (2011), 788–824.
2. Karampitsakos, T., Tzilas, V., Tringidou, R., Steiropoulos, P., Aidinis, V., Papiris, S.A., Bouros, D., Tzouvelekis, A., Lung cancer in patients with idiopathic pulmonary fibrosis. Pulm. Pharmacol. Therapeut. 42 (2017 Feb), 21–24.
3. Tzouvelekis, A., Tzilas, V., Papiris, S., Aidinis, V., Bouros, D., Diagnostic and prognostic challenges in Idiopathic Pulmonary Fibrosis: a patient's “Q and A” approach. Pulm. Pharmacol. Therapeut. 42 (2017), 21–24.
4. Tzilas, V., Valeyre, D., Tzouvelekis, A., Bouros, D., Taking a giant step in the diagnosis of idiopathic pulmonary fibrosis. Lancet Respir. Med., 2017 Nov 15 pii: S2213-2600(17)30443-5.
5. Tzouvelekis, A., Spagnolo, P., Bonella, F., Vancheri, C., Tzilas, V., Crestani, B., Kreuter, M., Bouros, D., Patients with IPF and lung cancer: diagnosis and management. Lancet Respir. Med., 2017 Dec 11 pii: S2213-2600(17)30478-2.
6. Tzouvelekis, A., Pneumatikos, I., Bouros, D., Serum biomarkers in acute respiratory distress syndrome an ailing prognosticator. Respir. Res., 6, 2005, 62.
7. Bouros, D., Tzouvelekis, A., Idiopathic pulmonary fibrosis: on the move. Lancet Resp. Med. 2 (2014), 17–19.
8. Spagnolo, P., Sverzellati, N., Rossi, G., Cavazza, A., Tzouvelekis, A., Crestani, B., Vancheri, C., Idiopathic pulmonary fibrosis: an update. Ann. Med. 47 (2015), 15–27.
9. Spagnolo, P., Tzouvelekis, A., Maher, T.M., Personalized medicine in idiopathic pulmonary fibrosis: facts and promises. Curr. Opin. Pulm. Med. 21 (2015), 470–478.
10. Tzouvelekis, A., Bonella, F., Spagnolo, P., Update on therapeutic management of idiopathic pulmonary fibrosis. Therapeut. Clin. Risk Manag. 11 (2015), 359–370.
11. Brown, A.W., Kaya, H., Nathan, S.D., Lung transplantation in IIP: a review. Respirology 21 (2016), 1173–1184.
12. Yu, G., Tzouvelekis, A., Wang, R., Herazo-Maya, J.D., Ibarra, G.H., Srivastava, A., de Castro, J.P.W., DeIuliis, G., Ahangari, F., Woolard, T., Aurelien, N., Arrojo, E.D.R., Gan, Y., Graham, M., Liu, X., Homer, R.J., Scanlan, T.S., Mannam, P., Lee, P.J., Herzog, E.L., Bianco, A.C., Kaminski, N., Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function. Nat. Med. 24 (2018), 39–49.
13. Fletcher, S., Jones, M.G., Spinks, K., Sgalla, G., Marshall, B.G., Limbrey, R., Richeldi, L., The safety of new drug treatments for idiopathic pulmonary fibrosis. Expet Opin. Drug Saf. 15 (2016), 1483–1489.
14. Tzouvelekis, A., Bouros, E., Tzilas, V., Bouros, D., Pirfenidone in idiopathic pulmonary fibrosis “RECAP-itulating safety into the real world”. Resp.; Int. Rev. Thoracic Dis. 94 (2017), 405–407.
15. Tzouvelekis, A., Ntolios, P., Karampitsakos, T., Tzilas, V., Anevlavis, S., Bouros, E., Steiropoulos, P., Koulouris, N., Stratakos, G., Froudarakis, M., Bouros, D., Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: a real-world observational study. Pulm. Pharmacol. Therapeut. 46 (2017), 48–53.
16. Tzouvelekis, A., Karampitsakos, T., Ntolios, P., Tzilas, V., Bouros, E., Markozannes, E., Malliou, I., Anagnostopoulos, A., Granitsas, A., Steiropoulos, P., Dimakou, K., Chrysikos, S., Koulouris, N., Bouros, D., Longitudinal “Real-World” outcomes of pirfenidone in idiopathic pulmonary fibrosis in Greece. Front. Med., 4, 2017, 213.
17. Hilberg, F., Roth, G.J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., Heckel, A., Rettig, W.J., BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Canc. Res. 68 (2008), 4774–4782.
18. Tai, W.T., Shiau, C.W., Li, Y.S., Chang, C.W., Huang, J.W., Hsueh, T.T., Yu, H.C., Chen, K.F., Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity. J. Hepatol. 61 (2014), 89–97.
19. Tzouvelekis, A., Yu, G., Lino Cardenas, C.L., Herazo-Maya, J.D., Wang, R., Woolard, T., Zhang, Y., Sakamoto, K., Lee, H., Yi, J.S., DeIuliis, G., Xylourgidis, N., Ahangari, F., Lee, P.J., Aidinis, V., Herzog, E.L., Homer, R., Bennett, A.M., Kaminski, N., SH2 domain-containing Phosphatase-2 is a novel antifibrotic regulator in pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 195 (2017), 500–514.
20. Tomos, I.P., Tzouvelekis, A., Aidinis, V., Manali, E.D., Bouros, E., Bouros, D., Papiris, S.A., Extracellular matrix remodeling in idiopathic pulmonary fibrosis. It is the 'bed' that counts and not 'the sleepers'. Expet Rev. Respir. Med. 11 (2017), 299–309.
21. Ryu, C., Sun, H., Gulati, M., Herazo-Maya, J.D., Chen, Y., Osafo-Addo, A., Brandsdorfer, C., Winkler, J., Blaul, C., Faunce, J., Pan, H., Woolard, T., Tzouvelekis, A., Antin-Ozerkis, D.E., Puchalski, J.T., Slade, M., Gonzalez, A.L., Bogenhagen, D.F., Kirillov, V., Feghali-Bostwick, C., Gibson, K., Lindell, K., Herzog, R.I., Dela Cruz, C.S., Mehal, W., Kaminski, N., Herzog, E.L., Trujillo, G., Extracellular mitochondrial DNA is generated by fibroblasts and predicts death in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 196 (2017), 1571–1581.
22. Richeldi, L., Costabel, U., Selman, M., Kim, D.S., Hansell, D.M., Nicholson, A.G., Brown, K.K., Flaherty, K.R., Noble, P.W., Raghu, G., Brun, M., Gupta, A., Juhel, N., Kluglich, M., du Bois, R.M., Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med. 365 (2011), 1079–1087.
23. Richeldi, L., du Bois, R.M., Raghu, G., Azuma, A., Brown, K.K., Costabel, U., Cottin, V., Flaherty, K.R., Hansell, D.M., Inoue, Y., Kim, D.S., Kolb, M., Nicholson, A.G., Noble, P.W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., Collard, H.R., Investigators, I.T., Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 370 (2014), 2071–2082.
24. Richeldi, L., Cottin, V., du Bois, R.M., Selman, M., Kimura, T., Bailes, Z., Schlenker-Herceg, R., Stowasser, S., Brown, K.K., Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS® trials. Respir. Med. 113 (2016), 74–79.
25. Cottin, V., The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis. Expet Opin. Drug Saf. 16 (2017), 857–865.
26. Corte, T., Bonella, F., Crestani, B., Demedts, M.G., Richeldi, L., Coeck, C., Pelling, K., Quaresma, M., Lasky, J.A., Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir. Res., 16, 2015, 116.
27. Bonella, F., Kreuter, M., Hagmeyer, L., Neurohr, C., Keller, C., Kohlhaeufl, M.J., Muller-Quernheim, J., Milger, K., Prasse, A., Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis. Resp.; Int. Rev. Thoracic Dis. 92 (2016), 98–106.
28. Fletcher, S., Jones, M., Renzoni, E., Parfrey, H., Hoyles, R., Spinks, K., Kokosi, M., Kwok, A., Warburton, C., Titmuss, V., Maher, T., Chua, F., Wells, A., Richeldi, L., Spencer, L., P9 Nintedanib for the treatment of Idiopathic Pulmonary Fibrosis – initial clinical experience in a UK cohort. Thorax, 70, 2015, A78.
29. Hughes, G., Toellner, H., Morris, H., Leonard, C., Chaudhuri, N., Real world experiences: pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis. J. Clin. Med., 5, 2016.
30. Noth, I.A.A., Kaul, M., et al. Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF): one-year data from post-marketing surveillance in the United States. QJM, 109(suppl 1), 2016 S51–2.
31. Pereira, C.B.-M.J., Guedes Baldi, B., et al. Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in Brazil. Poster presented at: Congresso Sociedade Brasileira de Pneumologia e Tisiologia (SBPT) [Congress of the Brazilian Society of Pneumology and Physiology], 2016 Oct 11‒15 Brazil).
32. Hajari Case, A., Johnson, P., Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis. BMJ Open Resp. Res., 4, 2017.
33. Crestani, B.O.T., Pelling, K., et al. Long-term treatment with nintedanib in patients with idiopathic pulmonary fibrosis: an update from INPULSIS®-ON. Paper Presented at: European Respiratory Society (ERS) International Congress; 2016 Sept 3‒7; London,UK, 2016.
34. Kontou, M., Bousgou, V., Tzilas, V., Bouros, E., Tsipilis, S., Granitsas, A., Marozanes, E., Dionelis, G., Koulouris, N., Bouros, D., Clinical experience with nintedanib for the treatment of IPF in 80 cases. Eur. Respir. J., 48, 2016.
35. Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C.A., Azuma, A., Behr, J., Brozek, J.L., Collard, H.R., Cunningham, W., Homma, S., Johkoh, T., Martinez, F.J., Myers, J., Protzko, S.L., Richeldi, L., Rind, D., Selman, M., Theodore, A., Wells, A.U., Hoogsteden, H., Schunemann, H.J., An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am. J. Respir. Crit. Care Med. 192 (2015), e3–19.
36. King, C.S., Nathan, S.D., POINT: should all patients with idiopathic pulmonary fibrosis, even those with more than moderate impairment, Be treated with nintedanib or pirfenidone?. Yes. Chest 150 (2016), 273–275.
37. Wuyts, W.A., Kolb, M., Stowasser, S., Stansen, W., Huggins, J.T., Raghu, G., First data on efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and forced vital capacity of
38. Costabel, U., Inoue, Y., Richeldi, L., Collard, H.R., Tschoepe, I., Stowasser, S., Azuma, A., Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am. J. Respir. Crit. Care Med. 193 (2016), 178–185.
39. Ogura, T., Taniguchi, H., Azuma, A., Inoue, Y., Kondoh, Y., Hasegawa, Y., Bando, M., Abe, S., Mochizuki, Y., Chida, K., Kluglich, M., Fujimoto, T., Okazaki, K., Tadayasu, Y., Sakamoto, W., Sugiyama, Y., Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J. 45 (2015), 1382–1392.
40. Bonella, F., Stowasser, S., Wollin, L., Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib. Drug Des. Dev. Ther. 9 (2015), 6407–6419.
41. Kolb, M., Richeldi, L., Behr, J., Maher, T.M., Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax 72 (2017), 340–346.
42. Maher, T.M., Flaherty, K.R., Noble, P.W., Vancheri, C., Wuyts, W.A., Kimura, T., Hallmann, C., Stowasser, S., Richeldi, L., Effect of baseline FVC on lung function decline with nintedanib in patients with IPF. Eur. Respir. J., 2015, 46.
43. Karimi-Shah, B.A., Chowdhury, B.A., Forced vital capacity in idiopathic pulmonary fibrosis — FDA review of pirfenidone and nintedanib. N. Engl. J. Med. 372 (2015), 1189–1191.
44. Schmidt, S.L., Tayob, N., Han, M.K., Zappala, C., Kervitsky, D., Murray, S., Wells, A.U., Brown, K.K., Martinez, F.J., Flaherty, K.R., Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest 145 (2014), 579–585.
45. Karampitsakos, T., Woolard, T., Bouros, D., Tzouvelekis, A., Toll-like receptors in the pathogenesis of pulmonary fibrosis. Eur. J. Pharmacol. 808 (2017), 35–43.